SAPIEN 3经导管主动脉瓣置换与外科瓣膜置换在中危患者中的结局比较
本研究通过倾向评分匹配,比较PARTNER 2 S3单臂研究中接受SAPIEN 3经导管主动脉瓣置换(TAVR)的中危患者与PARTNER 2A随机临床试验中接受外科主动脉瓣置换(SAVR)的中危患者5年结局。共匹配783对患者,结果显示两组主要复合终点(全因死亡和致残性卒中)无显著差异(40.2% vs 42.7%;HR: 0.87;95% CI: 0.74-1.03;P = 0.10)。SAPIEN 3 TAVR术后轻度或以上瓣周反流更常见,但结构性瓣膜衰败相关2期和3期血流动力学瓣膜衰败或生物瓣膜失败无差异。
要点
- 中危患者SAPIEN 3 TAVR与SAVR的5年全因死亡和致残性卒中复合终点无显著差异。
- SAPIEN 3 TAVR术后轻度或以上瓣周反流发生率高于SAVR。
- 两组结构性瓣膜衰败相关血流动力学瓣膜衰败或生物瓣膜失败无差异。
核心结论
- 在中危重度主动脉瓣狭窄患者的倾向匹配分析中,SAPIEN 3 TAVR与SAVR的5年死亡和致残性卒中发生率相似。
- SAPIEN 3 TAVR术后瓣周反流更常见,但结构性瓣膜衰败相关血流动力学瓣膜衰败无差异。
研究设计与样本
- 采用倾向评分匹配,比较PARTNER 2 S3单臂研究中接受SAPIEN 3 TAVR的中危患者与PARTNER 2A随机临床试验中接受SAVR的中危患者。
- 共纳入783对匹配的中危重度主动脉瓣狭窄患者。
- 主要复合终点为5年全因死亡和致残性卒中。
主要发现
- SAPIEN 3 TAVR与SAVR的5年主要复合终点发生率分别为40.2%和42.7%(HR: 0.87;95% CI: 0.74-1.03;P = 0.10)。
- SAPIEN 3 TAVR术后轻度或以上瓣周反流更常见。
- 两组结构性瓣膜衰败相关2期和3期血流动力学瓣膜衰败或生物瓣膜失败无差异。
临床怎么用
- 在中危重度主动脉瓣狭窄患者中,SAPIEN 3 TAVR可作为SAVR的替代选择,5年死亡和致残性卒中风险相似。
- 选择SAPIEN 3 TAVR时需考虑瓣周反流风险较高,术后应关注瓣周反流评估。
局限性
- SAPIEN 3 TAVR组来自单臂研究,SAVR组来自随机临床试验,非直接随机比较。
- 需要更长期随访以进一步评估晚期不良临床事件和生物瓣膜耐久性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies demonstrated transcatheter aortic valve replacement (TAVR) with an earlier generation balloon-expandable valve to be noninferior to surgical aortic valve replacement (SAVR) for death and disabling stroke in intermediate-risk patients with symptomatic, severe aortic stenosis at 5 years. However, limited long-term data are available with the more contemporary SAPIEN 3 (S3) bioprosthesis. OBJECTIVES: The aim of this study was to compare 5-year risk-adjusted outcomes in intermediate-risk patients undergoing S3 TAVR vs SAVR. METHODS: Propensity score matching was performed to account for baseline differences in intermediate-risk patients undergoing S3 TAVR in the PARTNER 2 (Placement of Aortic Transcatheter Valves) S3 single-arm study and SAVR in the PARTNER 2A randomized clinical trial. The primary composite endpoint consisted of 5-year all-cause death and disabling stroke. RESULTS: A total of 783 matched pairs of intermediate-risk patients with severe aortic stenosis were studied. There were no differences in the primary endpoint between S3 TAVR and SAVR at 5 years (40.2% vs 42.7%; HR: 0.87; 95% CI: 0.74-1.03; P = 0.10). The incidence of mild or greater paravalvular regurgitation was more common after S3 TAVR. There were no differences in structural valve deterioration-related stage 2 and 3 hemodynamic valve deterioration or bioprosthetic valve failure. CONCLUSIONS: In this propensity-matched analysis of intermediate-risk patients, 5-year rates of death and disabling stroke were similar between S3 TAVR and SAVR. Rates of structural valve deterioration-related hemodynamic valve deterioration were similar, but paravalvular regurgitation was more common after S3 TAVR. Longer-term follow-up is needed to further evaluate differences in late adverse clinical events and bioprosthetic valve durability. (PII S3i [PARTNER II Trial: Placement of Aortic Transcatheter Valves II - S3 Intermediate], NCT03222128; PII A (PARTNER II Trial: Placement of Aortic Transcatheter Valves II - XT Intermediate and High Risk], NCT01314313).
引用
- Madhavan MV, Kodali SK, Thourani VH, et al. Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. 2023. PMID: 37407110. doi:10.1016/j.jacc.2023.04.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。